No Approved Pharmacotherapy for Acute Methamphetamine Withdrawal
There is currently no medication with sufficient evidence to recommend for the treatment of acute methamphetamine withdrawal, and the most recent 2026 British Association for Psychopharmacology guidelines explicitly identify this as a key uncertainty in the field 1.
Current Evidence Landscape
The evidence base for pharmacological management of methamphetamine withdrawal remains extremely limited and of poor quality. A 2023 systematic review and meta-analysis found insufficient evidence to indicate any medication is effective for methamphetamine withdrawal, with quality of evidence ranging from low to very low 2. The 2026 BAP guidelines reinforce this, stating: "What is the best way to pharmacologically manage symptoms of stimulant withdrawal?" remains an unresolved key uncertainty 1.
Supportive Care Approach
Given the absence of evidence-based pharmacotherapy, the recommended approach is:
Primary Management
- Provide a supportive environment during the withdrawal period 3
- Withdrawal from methamphetamine is best undertaken in a supportive setting without specific medication for the withdrawal syndrome itself 3
Symptomatic Treatment Only
- Use symptomatic medications for specific symptoms as they arise:
- Agitation: Consider short-term benzodiazepines or other sedatives
- Sleep disturbance: Symptomatic sleep aids
- Monitor closely for depression or psychosis during withdrawal 3
Medications With Limited Preliminary Evidence
While not recommended as standard treatment, some medications have shown preliminary signals in research contexts:
Mirtazapine
- Two small trials showed conflicting results 1
- One trial found reduction in hyperarousal and anxiety symptoms
- A second trial found no benefit over placebo
- Not sufficient evidence to recommend 4
Amineptine
- Showed reduction in discontinuation rates in older studies 2, 4
- No longer available due to abuse liability concerns 4
- Not a viable treatment option
Naltrexone-Bupropion Combination
- One large RCT found long-acting injectable naltrexone combined with extended-release bupropion reduced methamphetamine use 1
- This evidence is for relapse prevention/ongoing use, not acute withdrawal 1
- Not specifically studied for withdrawal symptoms
Special Considerations
Methamphetamine-Associated Psychosis
If psychotic symptoms emerge during withdrawal:
- Antipsychotic agents can be used to treat methamphetamine-associated psychosis 1
- Olanzapine or quetiapine may be preferred based on low-quality evidence 1
- Requires close monitoring and specialist consultation when available 3
Depression During Withdrawal
- Monitor closely for emergence of depression 3
- May require specialist psychiatric consultation
- Consider standard antidepressant treatment if clinically indicated
Critical Pitfalls to Avoid
Do not use prescription stimulants (methylphenidate, dexamphetamine) for acute withdrawal - current evidence does not support their use for withdrawal management 1
Do not treat withdrawal as a standalone intervention - it should be part of comprehensive treatment with psychosocial support and assertive onward referral 1
Do not assume cocaine withdrawal treatments apply - despite common clinical practice of using cocaine withdrawal medications for methamphetamine, these are pharmacologically distinct substances 4
Integration with Ongoing Treatment
Medically assisted withdrawal should rarely be standalone except in emergencies 1. The focus should be on:
- Stabilization in a supportive environment
- Symptom management as needed
- Immediate linkage to psychosocial interventions (contingency management shows 40-60% increase in abstinence rates) 5
- Planning for relapse prevention strategies once acute withdrawal resolves
The evidence clearly indicates that supportive care with symptomatic treatment remains the standard approach until higher-quality trials establish effective pharmacotherapy for methamphetamine withdrawal 2, 6.